Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Q32 BioSTU:DB0 +1.66%17 Debt-to-EBITDA is -0.15 as of Jun. 2026. GuruFocus rates STU:DB0 with a GF Score™ of 17/100. The stock has 6 warning signs investors should review. Among 298 Biotechnology companies, Q32 Bio ranks better than 67.79% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Q32 Bio's Debt-to-EBITDA or its related term are showing as below:
STU:DB0'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.15 Med: -0.43 Max: 0.49
Current: 0.4
During the past 5 years, the highest Debt-to-EBITDA Ratio of Q32 Bio was 0.49. The lowest was -1.15. And the median was -0.43.
STU:DB0's Debt-to-EBITDA is ranked better than 67.79% of 298
companies
in the Biotechnology industry
Industry Median: 1.23
vs STU:DB0: 0.40
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Q32 Bio Debt-to-EBITDA Related Terms
Q32 Bio Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Q32 Bio's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:DB0 vs KYTX, PRTA, CABA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Q32 Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q32 Bio Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Q32 Bio's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Q32 Bio's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Q32 Bio (STU:DB0) has a Debt-to-EBITDA of -0.15 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Q32 Bio. According to the industry distribution chart, Q32 Bio ranks #96 out of 298 companies in the Biotechnology industry, placing it in the top 32.2%.
Is Q32 Bio's Debt-to-EBITDA too high?
Q32 Bio's current Debt-to-EBITDA is -0.15. Based on the distribution chart, Q32 Bio ranks #96 out of 298 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's Debt-to-EBITDA compare to KYTX and PRTA?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #96 out of 298 companies for Debt-to-EBITDA. This puts Q32 Bio in the upper half of its industry. The industry median Debt-to-EBITDA is 1.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.23, based on 298 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Q32 Bio. For the Biotechnology industry, the median Debt-to-EBITDA is 1.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q32 Bio's current Debt-to-EBITDA is -0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (STU:DB0) has a current Debt-to-EBITDA of -0.15. The current Debt-to-EBITDA is -0.15. Q32 Bio's overall GF Score™ is 17/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Q32 Bio (STU:DB0), the current Debt-to-EBITDA is -0.15 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score
Get the complete analysis for STU:DB0
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:DB0 has been successfully added to your 
